Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
Bourgoin early development hub broadens offerings for oral solid dose formulations
Miravo to remain a Canadian controlled and operated company following closing of the transaction
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
Subscribe To Our Newsletter & Stay Updated
